AcelRx Pharmaceuticals, Inc. (ACRX) News
Filter ACRX News Items
ACRX News Results
|Loading, please wait...|
ACRX News Highlights
- For ACRX, its 30 day story count is now at 4.
- Over the past 2 days, the trend for ACRX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- PRE are the most mentioned tickers in articles about ACRX.
Latest ACRX News From Around the Web
Below are the latest news stories about ACELRX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACRX as an investment opportunity.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript November 14, 2022 AcelRx Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.94, expectations were $-1.2. Operator: Welcome to the AcelRx Third Quarter 2022 Earnings Call. This call is being webcast live via the Events page of the Investors section of AcelRx’s website at www.acelrx.com. This […]
AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
HAYWARD, Calif., Dec. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has entered into an…
AcelRx Pharmaceuticals (ACRX) announced plans sell ~$7.5M worth of registered direct offering of common stock and warrants on Tuesday, sending its shares lower. Read the full story here.
AcelRx Pharmaceuticals (NASDAQ: ACRX ) brought in sales totaling $507 thousand during Q3 according to data provided by Benzinga Pro . However, earnings decreased 109.55%, resulting in a loss of $6.75 million. In Q2, AcelRx Pharmaceuticals earned $70.66 million, and total sales reached $570 thousand. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com
In this article, we discuss the 10 cheapest stocks with the biggest upside. If you want to read about some more cheapest stocks with the biggest upside, go directly to 5 Cheapest Stocks With Biggest Upside. According to the advance estimate released by the Bureau of Economic Analysis in late October 2022, the real gross […]
AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a recent retrospective study published in the Journal of Clinical Medicine Special Issue "Advances in Postoperative Pain Management and Postoperative Chronic Pain". The study was lead-authored by orthopedic surgeon Dr. Andrea Angelini and entitled "Sublingual Sufentanil Tablet S
AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) Declined -40.84% Over The Last Month – Are There Ways To Succeed From This Decline?
During the last session, AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)’s traded shares were 0.43 million, with the beta value of the company hitting 0.25. At the end of the trading day, the stock’s price was $2.39, reflecting an intraday loss of -1.24% or -$0.03. The 52-week high for the ACRX share is $14.98, that puts it down … AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) Declined -40.84% Over The Last Month – Are There Ways To Succeed From This Decline? Read More »
AcelRx Pharmaceuticals ( NASDAQ:ACRX ) Third Quarter 2022 Results Key Financial Results Net loss: US$6.75m (loss...
Initial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization submission DSUVIA sales of $0.5M in the third quarter, a 217% increase over prior year $20.9 million in cash and short-term investments as of September 30, 2022 Webcast and…
AcelRx Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ACRX) Q3 2022 Results Earnings Conference Call November 14, 2022, 04:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer…